Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sajitha Sachchithanantham

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
European Journal of Haematology|January 18, 2021
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UKFaye A Sharpley, Richa Manwani, Aviva Petrie, et al.
Blood Cancer Journal|May 24, 2020
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosisOliver C Cohen, Steven Law, Helen J Lachmann, et al.
Haematologica|September 7, 2014
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed settingChristopher P Venner, Julian D Gillmore, Sajitha Sachchithanantham, et al.
Kidney International|July 22, 2017
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factorTamer Rezk, Helen J Lachmann, Marianna Fontana, et al.
British Journal of Haematology|August 8, 2019
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathyRicha Manwani, Shameem Mahmood, Sajitha Sachchithanantham, et al.
The Lancet. Haematology|December 22, 2015
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational studyShameem Mahmood, Frank Bridoux, Christopher P Venner, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 8, 2017
Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centreThirusha Lane, Jennifer H Pinney, Janet A Gilbertson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 6, 2018
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosisTamer Rezk, Janet A Gilbertson, Dorota Rowczenio, et al.
British Journal of Haematology|May 25, 2019
Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkersTamer Rezk, Helen J Lachmann, Marianna Fontana, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 yearJohn-Paul Carter, Darren Foard, Lisa Rannigan, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
European Journal of Haematology|January 18, 2021
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UKFaye A Sharpley, Richa Manwani, Aviva Petrie, et al.
Blood Cancer Journal|May 24, 2020
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosisOliver C Cohen, Steven Law, Helen J Lachmann, et al.
Haematologica|September 7, 2014
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed settingChristopher P Venner, Julian D Gillmore, Sajitha Sachchithanantham, et al.
Kidney International|July 22, 2017
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factorTamer Rezk, Helen J Lachmann, Marianna Fontana, et al.
British Journal of Haematology|August 8, 2019
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathyRicha Manwani, Shameem Mahmood, Sajitha Sachchithanantham, et al.
The Lancet. Haematology|December 22, 2015
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational studyShameem Mahmood, Frank Bridoux, Christopher P Venner, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 8, 2017
Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centreThirusha Lane, Jennifer H Pinney, Janet A Gilbertson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 6, 2018
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosisTamer Rezk, Janet A Gilbertson, Dorota Rowczenio, et al.
British Journal of Haematology|May 25, 2019
Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkersTamer Rezk, Helen J Lachmann, Marianna Fontana, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 yearJohn-Paul Carter, Darren Foard, Lisa Rannigan, et al.
Pageof 6